Lifeward Ltd. (LFWD) Q4 2025 Earnings Call March 18, 2026 8:30 AM EDT
Company Participants
Almog Adar – Chief Financial Officer
William Grant – President & CEO
Conference Call Participants
Yale Jen – Laidlaw & Company (UK) Ltd., Research Division
Swayampakula Ramakanth – H.C. Wainwright & Co, LLC, Research Division
Presentation
Operator
Good day, and welcome to the Lifeward Inc. Fourth Quarter 2025 Earnings Conference Call. [Operator Instructions]. Please note, today’s event is being recorded. I would now like to turn the conference over to Almog Adar, Chief Financial Officer. Please go ahead.
Almog Adar
Chief Financial Officer
Thank you, Aku, and thanks, everyone who joined us on the call today. My name is Almog Adar, I’m Lifeward Chief Financial Officer. And with me on today’s call is our President and Chief Executive Officer, Mark Grant.
Earlier this morning, Lifeward issued a press release detailing the financial results for the fourth quarter and the full year ended December 31, 2025. I would ask you to review the full text of our forward-looking statements from the press release. We anticipate making projections during this call, and actual results could differ materially due to several factors, including those outlined in our latest filings with the SEC. And with that, I will turn the call over to Mark.
William Grant
President & CEO
Good morning, and thanks, everyone, for joining us on the call today. Before we get into the details of the quarter and the year, I want to start with what we believe is fundamental to the Lifeward investment thesis today. We’re executing against a strategy to build a leading, diversified, biomedical innovation company with multiple technology platforms and strong clinical foundations.
Importantly, we’re establishing a clear line of sight to scale through continued progress in reimbursement, commercial execution and product innovation. Our strategic
